Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BMN 255

Other · developed by BioMarin Pharmaceutical

Phase 1 Most advanced trial (none active)
BMRN Developer
1 Registered trials

What is BMN 255?

BMN 255 is an investigational agent studied in hyperoxaluria, nonalcoholic fatty liver disease and kidney stones.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Gastroenterology, Renal & urology
Developer
BioMarin Pharmaceutical (BMRN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
WC82E7HRU5

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06138327 Phase 1 Hyperoxaluria Withdrawn BMRN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HyperoxaluriaKidney StoneNonalcoholic Fatty Liver Disease

More from BioMarin Pharmaceutical

Follow BMRN, the company behind BMN 255

See BMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMRN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.